Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Wedbush initiated coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an outperform rating and a $40.00 price objective for the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a buy rating and a $40.00 price target for the company. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of Buy and an average target price of $41.25.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $24.82 on Monday. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.